Hopes for a vaccine against cervical cancer after mouse trials showed it reduced tumors in 80 percent of cases
- Researchers at the University of Pennsylvania and Sao Paulo have been trialling vaccines
- 80% of the mice tested with three vaccines showed complete tumor regression
Scientists are one step closer to developing a vaccine against cervical cancer after trials in mice showed it reduced tumors in 80 percent of cases.
Researchers tested three mRNA vaccines – the basis of which was the Covid shot – on tumors caused by the human papillomavirus (HPV).
Although HPV does not cause problems for most people, it can increase the risk of some types of cancer, such as cervical cancer.
The three vaccines were tested individually on mice with HPV tumors – and analysis of the results published in the journal Science Translational Medicine found that each vaccine was able to reduce the size of the tumors with a single dose.
The researchers reported complete tumor regression in 80% of the test mice
“Even a few low doses of the vaccines elicited strong immune responses and led to complete tumor regression in 80 percent of the mice at an advanced stage,” said the team from the Universities of Pennsylvania and São Paulo.
A vaccine already given to young people can protect against HPV and prevent cancers caused by it, but it does not treat tumors.
The findings were presented at the conference of the American Association for the Advancement of Science in Washington.
Further clinical trials will be needed, the team explained.